Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: Results from a pilot observational study

Inflammatory Bowel Diseases

Volumn 20, Issue 11, 2014, Pages 1996-2003

  Vaughn, Byron P ^a   Martinez Vazquez, Manuel ^a   Patwardhan, Vilas R ^a   Moss, Alan C ^a   Sandborn, William J ^b   Cheifetz, Adam S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inflammatory bowel disease; Infliximab; Infliximab concentration; Optimized monotherapy; Therapeutic drug monitoring

Indexed keywords

ANTIBODY; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MONITORING; DRUG WITHDRAWAL; DYSPLASIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATORY BOWEL DISEASE; LIMIT OF DETECTION; LUPUS LIKE SYNDROME; MAINTENANCE THERAPY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT MONITORING; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SECONDARY ANALYSIS; SENSITIVITY ANALYSIS; SIDE EFFECT; TERTIARY CARE CENTER; THERAPEUTIC CONCENTRATION MONITORING; TREATMENT DURATION; BLOOD; CASE CONTROL STUDY; FOLLOW UP; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; PROGNOSIS; TISSUE DISTRIBUTION;

ADULT; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION;

EID: 84925623006     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000156     Document Type: Article

References (26)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2005;359: 1541-1549.
2. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008:CD006893.
3. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
5. Colombel J-F, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
6. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104:760-767.
7. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
8. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2012;108: 40-47.
9. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
10. Radstake TRDJ, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739-1745.
11. Yamada A, Sono K, Hosoe N, et al. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis. 2010; 16:1898-1904.
12. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis. 2013;7:736-743.
13. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2009;59:49-54.
14. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
15. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2568-2576.
16. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin Pharmacokinet. 2009;48:419-462.
17. Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025-1031.
18. Ziring DA, Wu SS, Mow WS, et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr. 2007;45:306-311.
19. Zelenitsky S, Rubinstein E, Ariano R, et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents. 2013;41: 255-260.
20. Hansen M, Christrup LL, Jarløv JO, et al. Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand. 2001;45:734-740.
21. Colombel J-F, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:349-358.
22. Casteele NV, Gils A, Ballet V, et al. Randomizsed Controlled Trial of Drug Level Versus Clinically Based Dosing of Infliximab Maintenance Therapy in IBD: Final Results of the Taxit Study. Paper presented at: The 21st United European Gastroenterology Week; October 12-16, 2013; Berlin, Germany.
23. Steenholdt C, Ainsworth MA, Tovey M, et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit. 2013;35:530-538.
24. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. [published online ahead of print March 4, 2014]. doi: 10.1136/gutjnl-2012-304094.
25. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182.
26. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut. 2009;58:492-500.